A naukri.com initiative
Bioengineer
1w
351
Image Credit: Bioengineer
Revolutionary Amplification-Free Electrochemiluminescent Biosensor Enables Ultra-Sensitive Detection of Fusobacterium nucleatum via Tetrahedral DNA-Based CRISPR/Cas12a Technology
- A groundbreaking amplification-free electrochemical biosensor has been developed to detect Fusobacterium nucleatum, known for its correlation with colorectal cancer.
- Utilizing CRISPR/Cas12a technology, the biosensor integrates tetrahedral DNA nanostructures and coralliform gold nanostructures to enhance detection efficiency.
- Electrochemiluminescence plays a crucial role in the biosensing platform, offering sensitivity and enabling reliable detection of target nucleic acids.
- The biosensor operates without amplification techniques, achieving remarkable detection limits and demonstrating practicality in clinical settings.
- Adaptability is a key feature, with the biosensor's design allowing for tailored detection of various nucleic acids and pathogens for diverse diagnostic applications.
- The biosensor's performance relies on specific interactions between tetrahedral DNA nanostructures, Cas12a enzyme, and the target gene present in F. nucleatum.
- Exceptional linear detection range and high mismatch sensitivity enable differentiation between wild-type sequences and mutations, aiding in accurate diagnostics.
- The biosensor's implications for infectious disease diagnosis, especially in early detection for effective treatment, could transform healthcare practices.
- Funding from organizations like the China Postdoctoral Science Foundation supports collaborative efforts to advance biosensing technologies for improving healthcare outcomes.
- Research led by Jieling Qin at the Beijing Institute of Technology showcases significant advancements in biosensing for disease detection and treatment.
Read Full Article
21 Likes
For uninterrupted reading, download the app